Katherine A. Hoadley, Ph.D.
Affiliations: | 2006 | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Bioinformatics, Genetics, OncologyGoogle:
"Katherine Hoadley"Parents
Sign in to add mentor| Charles M. Perou | grad student | 2006 | UNC Chapel Hill | |
| (Development of biologically based therapies for basal-like breast tumors.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fernandez-Martinez A, Rediti M, Tang G, et al. (2024) Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. Jama Oncology |
| Zagami P, Fernandez-Martinez A, Rashid NU, et al. (2023) Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. Jama Network Open. 6: e2348814 |
| Xiang S, Zhang W, Liu S, et al. (2023) PAIRWISE NONLINEAR DEPENDENCE ANALYSIS OF GENOMIC DATA. The Annals of Applied Statistics. 17: 2924-2943 |
| Sturgill IR, Raab JR, Hoadley KA. (2023) Expanded detection of alterations in cancer and tumor type-specific expression score comparison. Biorxiv : the Preprint Server For Biology |
| Shi Y, Olsson LT, Hoadley KA, et al. (2023) Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study. Npj Breast Cancer. 9: 92 |
| Rediti M, Fernandez-Martinez A, Venet D, et al. (2023) Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. 14: 7053 |
| Tovey H, Sipos O, Parker JS, et al. (2023) Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF15 |
| Hamilton AM, Van Alsten SC, Gao X, et al. (2023) Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. Cancer Research Communications. 3: 12-20 |
| McClure MB, Kogure Y, Ansari-Pour N, et al. (2023) Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals Aneuploidy-driven Metabolic Reprogramming. Cancer Research Communications. 3: 281-296 |
| Walens A, Olsson LT, Gao X, et al. (2023) Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation; a Journal of Technical Methods and Pathology. 101: 785-793 |